Cargando…
Outcome of Antibody‐Mediated Fetal Heart Disease With Standardized Anti‐Inflammatory Transplacental Treatment
BACKGROUND: Transplacental fetal treatment of immune‐mediated fetal heart disease, including third‐degree atrioventricular block (AVB III) and endocardial fibroelastosis, is controversial. METHODS AND RESULTS: To study the impact of routine transplacental fetal treatment, we reviewed 130 consecutive...
Autores principales: | Mawad, Wadi, Hornberger, Lisa, Cuneo, Bettina, Raboisson, Marie‐Josée, Moon‐Grady, Anita J., Lougheed, Jane, Diab, Karim, Parkman, Julia, Silverman, Earl, Jaeggi, Edgar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238501/ https://www.ncbi.nlm.nih.gov/pubmed/35001672 http://dx.doi.org/10.1161/JAHA.121.023000 |
Ejemplares similares
-
To Be or Not to Be: Surviving Immune‐Mediated Fetal Heart Disease
por: Jaeggi, Edgar, et al.
Publicado: (2022) -
Outcomes of sustained fetal tachyarrhythmias after transplacental treatment
por: Bartin, Raphael, et al.
Publicado: (2021) -
Transplacental transfer of genotoxins and transplacental carcinogenesis.
por: Autrup, H
Publicado: (1993) -
Transplacental Passage and Fetal Effects of Antineoplastic Treatment during Pregnancy
por: Triarico, Silvia, et al.
Publicado: (2022) -
Development and Validation of a Fetal Cardiovascular Disease Severity Scale
por: Davey, Brooke T., et al.
Publicado: (2014)